Androgen receptor (AR) is a member of the steroid and nuclear receptor superfamily, 1
which is composed of over 100 members and continues to grow. Among this large family of …

Carcinoma of the prostate is the most commonly diagnosed cancer in men. The current
pharmacological treatment of choice for progressive androgen-dependent prostate cancer is the …

Despite promising preclinical studies with the cyclin-dependent kinase inhibitor flavopiridol
in chronic lymphocytic leukemia (CLL) and other diseases, previous clinical trials with this …

Background Cachexia, also known as muscle wasting, is a complex metabolic condition
characterized by loss of skeletal muscle and a decline in physical function. Muscle wasting is …

Cancer cachexia is a complex metabolic condition characterized by loss of skeletal muscle.
Common clinical manifestations include muscle wasting, anemia, reduced caloric intake, …

Background Cancer-induced muscle wasting begins early in the course of a patient's
malignant disease, resulting in declining physical function and other detrimental clinical …

Several regulatory concerns have hindered development of androgens as anabolic therapies,
despite unequivocal evidence that testosterone supplementation increases muscle mass …

Nonsteroidal androgens have not been reported. During studies to identify affinity ligands for
the androgen receptor in our laboratory, we synthesized several electrophilic nonsteroidal …

Selective androgen receptor modulators (SARMs) are a novel class of androgen receptor (AR)
ligands that might change the future of androgen therapy dramatically. With improved …

The mechanism by which the androgen receptor (AR) distinguishes between agonist and
antagonist ligands is poorly understood. AR antagonists are currently used to treat prostate …